{"success":true,"data":{"pressRelease":{"id":"3943","rtpr_id":"nGNXbl3cDq","ticker":"SLNO","exchange":"NASDAQ","all_tickers":["SLNO"],"title":"Soleno Therapeutics, Inc. Notice of May 5, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline","author":"Globe Newswire","published_at":"2026-04-22T03:24:13.100Z","article_body":"NEW YORK and NEW ORLEANS, April 21, 2026 (GLOBE NEWSWIRE) -- Kahn Swick & Foti\n(https://ksfcounsel.com/), LLC (“KSF”) and KSF partner, former Attorney\nGeneral of Louisiana, Charles C. Foti, Jr., notifies investors in Soleno\nTherapeutics (https://www.ksfcounsel.com/cases/nasdaqcm-slno/), Inc.\n(“Soleno” or the “Company”) (NasdaqCM: SLNO) of a class action\nsecurities lawsuit.\n\nCLASS DEFINITION: The lawsuit seeks to recover losses on behalf of investors\nof Soleno Therapeutics who were adversely affected by alleged securities fraud\nbetween March 26, 2025 and November 4, 2025. Follow the link below to get more\ninformation and be contacted by a member of our team:\n\nhttps://www.ksfcounsel.com/cases/nasdaqcm-slno/\n\nSoleno investors should contact KSF Managing Partner Lewis Kahn toll-free at\n1-877-515-1850 or via email (lewis.kahn@ksfcounsel.com), or visit\nhttps://www.ksfcounsel.com/cases/nasdaqcm-slno/ to learn more.\n\nCASE DETAILS: According to the Complaint, Soleno and certain of its executives\nare charged with failing to disclose material information during the Class\nPeriod, violating federal securities laws.\n\nThe alleged false and misleading statements and/or omissions include, but are\nnot limited to, that: (i) The Phase 3 clinical trial program for DCCR, the\nCompany’s only commercial product (for the treatment of hyperphagia in\nindividuals afflicted with Prader-Willi syndrome or “PWS”), systematically\nminimized, mischaracterized, and/or failed to disclose substantial evidence of\npotential safety concerns associated with its administration, including\nindications of excessive fluid retention among clinical trial participants;\n(ii) as a result, the administration of DCCR to treat hyperphagia in\nindividuals with PWS posed materially greater safety risks than disclosed by\nthe Company; and (iii) consequently, DCCR had materially lower commercial\nviability and undisclosed risks related to the likelihood of significant and\nwidespread adverse events after its commercial launch, including risks related\nto patient discontinuation rates, lower patient adoption, prescriber\nreluctance, adverse regulatory action, and potential reputational and legal\nfallout.\n\nThe case is City of Pontiac Police and Fire Retirement System v. Soleno\nTherapeutics, Inc., No. 26-cv-01979.\n\nWHAT TO DO? If you invested in Soleno and suffered a loss during the relevant\ntime frame, you have until May 5, 2026 to request that the Court appoint you\nas lead plaintiff; however, your ability to share in any recovery does not\nrequire that you serve as a lead plaintiff.\n\nAbout Kahn Swick & Foti (https://www.youtube.com/watch?v=ERl52xsyj0s), LLC\n\nKSF, whose partners include former Louisiana Attorney General Charles C. Foti,\nJr., is one of the nation's premier boutique securities litigation law firms.\nThis past year, KSF was ranked by SCAS among the top 10 firms nationally based\nupon total settlement value. KSF serves a variety of clients, including public\nand private institutional investors, and retail investors - in seeking\nrecoveries for investment losses emanating from corporate fraud or malfeasance\nby publicly traded companies. KSF has offices in New York, Delaware,\nCalifornia, Louisiana, Chicago, and a representative office in Luxembourg.\n\nTOP 10 Plaintiff Law Firms - According to ISS Securities Class Action Services\n\nTo learn more about KSF, you may visit www.ksfcounsel.com.\n\nContact:\n\nKahn Swick & Foti, LLC\nLewis Kahn, Managing Partner\nlewis.kahn@ksfcounsel.com\n1-877-515-1850\n1100 Poydras St., Suite 960\nNew Orleans, LA 70163\n\nCONNECT WITH US: Facebook\n(https://www.facebook.com/profile.php?id=61575733915628) || Instagram\n(https://www.instagram.com/kahn_swick_and_foti/) || YouTube\n(https://www.youtube.com/@kahnswickandfoti) || TikTok\n(https://www.tiktok.com/@kahn.swick.foti) || LinkedIn\n(https://www.linkedin.com/company/ksfcounsel)\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/b66e75b8-42a3-4666-b8fa-64a468417619)\n\n\n\nGlobeNewswire, Inc. 2026","article_body_html":"","raw_payload":{"data":{"id":"nGNXbl3cDq","title":"Soleno Therapeutics, Inc. Notice of May 5, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline","author":"Globe Newswire","ticker":"SLNO","created":"2026-04-22T03:24:13.100Z","tickers":["SLNO"],"exchange":"NASDAQ","article_body":"NEW YORK and NEW ORLEANS, April 21, 2026 (GLOBE NEWSWIRE) -- Kahn Swick & Foti\n(https://ksfcounsel.com/), LLC (“KSF”) and KSF partner, former Attorney\nGeneral of Louisiana, Charles C. Foti, Jr., notifies investors in Soleno\nTherapeutics (https://www.ksfcounsel.com/cases/nasdaqcm-slno/), Inc.\n(“Soleno” or the “Company”) (NasdaqCM: SLNO) of a class action\nsecurities lawsuit.\n\nCLASS DEFINITION: The lawsuit seeks to recover losses on behalf of investors\nof Soleno Therapeutics who were adversely affected by alleged securities fraud\nbetween March 26, 2025 and November 4, 2025. Follow the link below to get more\ninformation and be contacted by a member of our team:\n\nhttps://www.ksfcounsel.com/cases/nasdaqcm-slno/\n\nSoleno investors should contact KSF Managing Partner Lewis Kahn toll-free at\n1-877-515-1850 or via email (lewis.kahn@ksfcounsel.com), or visit\nhttps://www.ksfcounsel.com/cases/nasdaqcm-slno/ to learn more.\n\nCASE DETAILS: According to the Complaint, Soleno and certain of its executives\nare charged with failing to disclose material information during the Class\nPeriod, violating federal securities laws.\n\nThe alleged false and misleading statements and/or omissions include, but are\nnot limited to, that: (i) The Phase 3 clinical trial program for DCCR, the\nCompany’s only commercial product (for the treatment of hyperphagia in\nindividuals afflicted with Prader-Willi syndrome or “PWS”), systematically\nminimized, mischaracterized, and/or failed to disclose substantial evidence of\npotential safety concerns associated with its administration, including\nindications of excessive fluid retention among clinical trial participants;\n(ii) as a result, the administration of DCCR to treat hyperphagia in\nindividuals with PWS posed materially greater safety risks than disclosed by\nthe Company; and (iii) consequently, DCCR had materially lower commercial\nviability and undisclosed risks related to the likelihood of significant and\nwidespread adverse events after its commercial launch, including risks related\nto patient discontinuation rates, lower patient adoption, prescriber\nreluctance, adverse regulatory action, and potential reputational and legal\nfallout.\n\nThe case is City of Pontiac Police and Fire Retirement System v. Soleno\nTherapeutics, Inc., No. 26-cv-01979.\n\nWHAT TO DO? If you invested in Soleno and suffered a loss during the relevant\ntime frame, you have until May 5, 2026 to request that the Court appoint you\nas lead plaintiff; however, your ability to share in any recovery does not\nrequire that you serve as a lead plaintiff.\n\nAbout Kahn Swick & Foti (https://www.youtube.com/watch?v=ERl52xsyj0s), LLC\n\nKSF, whose partners include former Louisiana Attorney General Charles C. Foti,\nJr., is one of the nation's premier boutique securities litigation law firms.\nThis past year, KSF was ranked by SCAS among the top 10 firms nationally based\nupon total settlement value. KSF serves a variety of clients, including public\nand private institutional investors, and retail investors - in seeking\nrecoveries for investment losses emanating from corporate fraud or malfeasance\nby publicly traded companies. KSF has offices in New York, Delaware,\nCalifornia, Louisiana, Chicago, and a representative office in Luxembourg.\n\nTOP 10 Plaintiff Law Firms - According to ISS Securities Class Action Services\n\nTo learn more about KSF, you may visit www.ksfcounsel.com.\n\nContact:\n\nKahn Swick & Foti, LLC\nLewis Kahn, Managing Partner\nlewis.kahn@ksfcounsel.com\n1-877-515-1850\n1100 Poydras St., Suite 960\nNew Orleans, LA 70163\n\nCONNECT WITH US: Facebook\n(https://www.facebook.com/profile.php?id=61575733915628) || Instagram\n(https://www.instagram.com/kahn_swick_and_foti/) || YouTube\n(https://www.youtube.com/@kahnswickandfoti) || TikTok\n(https://www.tiktok.com/@kahn.swick.foti) || LinkedIn\n(https://www.linkedin.com/company/ksfcounsel)\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/b66e75b8-42a3-4666-b8fa-64a468417619)\n\n\n\nGlobeNewswire, Inc. 2026"},"type":"article","timestamp":"2026-04-22T03:24:13.145564022Z","server_sent_at_ms":1776828253145},"received_at":"2026-04-22T03:24:13.199Z","source_url":null},"analysis":{"id":"2744","press_release_id":"3943","analysis_json":{"industry":{"label":"Pharmaceuticals, Biotechnology & Life Sciences","sector":"Health Care"},"redFlags":["Class action lawsuit alleges securities fraud","Allegations of undisclosed safety risks (excessive fluid retention) in Phase 3 trial for DCCR","Complaint alleges DCCR has materially lower commercial viability than disclosed"],"eventType":"legal_litigation","narrative":"Kahn Swick & Foti announced a class action lawsuit against Soleno Therapeutics on behalf of investors who purchased securities between March 26, 2025, and November 4, 2025.\n\nThe complaint alleges that the company failed to disclose material safety concerns, specifically excessive fluid retention, observed during the Phase 3 clinical trial program for DCCR.\n\nPlaintiffs claim these omissions overstated the commercial viability of DCCR, Soleno's only product indicated for the treatment of hyperphagia in Prader-Willi syndrome.","sentiment":"bearish","agentHooks":{"shouldPost":false,"suggestedAngle":"Securities fraud suit alleges Soleno hid safety data for lead asset DCCR."},"keyFigures":{"drugName":"DCCR","phaseOfTrial":"Phase 3"},"quotedText":"","namedEntities":{"people":[{"name":"Lewis Kahn","role":"Managing Partner"},{"name":"Charles C. Foti, Jr.","role":"Partner, former Attorney General of Louisiana"}],"products":["DCCR"],"companies":[{"name":"Kahn Swick & Foti, LLC","relationship":"plaintiff counsel"},{"name":"City of Pontiac Police and Fire Retirement System","relationship":"plaintiff"},{"name":"Soleno Therapeutics, Inc.","ticker":"SLNO"}],"dollarAmounts":[]},"materialImpact":{"score":3,"reasoning":"A class action lawsuit has been filed alleging securities fraud and failure to disclose material safety risks regarding the company's only commercial product, DCCR."},"tickerRelevance":{"others":[],"primary":"SLNO"},"eventTypeSecondary":[]},"event_type":"legal_litigation","event_type_secondary":null,"sentiment":"bearish","material_impact_score":3,"narrative":"Kahn Swick & Foti announced a class action lawsuit against Soleno Therapeutics on behalf of investors who purchased securities between March 26, 2025, and November 4, 2025.\n\nThe complaint alleges that the company failed to disclose material safety concerns, specifically excessive fluid retention, observed during the Phase 3 clinical trial program for DCCR.\n\nPlaintiffs claim these omissions overstated the commercial viability of DCCR, Soleno's only product indicated for the treatment of hyperphagia in Prader-Willi syndrome.","key_figures":{"drugName":"DCCR","phaseOfTrial":"Phase 3"},"named_entities":{"people":[{"name":"Lewis Kahn","role":"Managing Partner"},{"name":"Charles C. Foti, Jr.","role":"Partner, former Attorney General of Louisiana"}],"products":["DCCR"],"companies":[{"name":"Kahn Swick & Foti, LLC","relationship":"plaintiff counsel"},{"name":"City of Pontiac Police and Fire Retirement System","relationship":"plaintiff"},{"name":"Soleno Therapeutics, Inc.","ticker":"SLNO"}],"dollarAmounts":[]},"model_name":"glm-4.7","prompt_hash":"sha256:2f2748f0fcc8c4f2","schema_hash":"sha256:ad96b863d7123008","created_at":"2026-04-22T04:30:35.083Z","global_importance":3,"audience_relevance":3,"importance_components":{"method":"backfill-heuristic","signals":{"bodyLong":false,"headlineTier1":false,"tickerCovered":false,"hadSignificance":false},"version":1,"computedAt":"2026-04-27T11:52:53.845Z"}},"durationMs":77275,"modelName":"glm-4.7"}}